Navigation Links
Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division

SCARSDALE, N.Y., March 30 /PRNewswire/ -- Double Helix Consulting US, a division of London-based Double Helix Development group, today announced the appointment of Ann Stuchiner to the position of Vice President. Stuchiner joins a multidisciplinary team of highly experienced strategic pricing, reimbursement and market access consultants with extensive experience across the healthcare industry, which provide product commercialization services to firms in the pharmaceutical, biotechnology and medical device industries. DHC US provides services spanning the product lifecycle, including the following:

  • Product value message development and testing
  • Commercial assessment
  • Development program and clinical trial planning
  • Managed markets strategy
  • Pharmacoeconomic evaluation and health technology assessment
  • Payer and provider insight evaluation and influence planning
  • Pricing and reimbursement strategy, negotiation simulation, and training
  • Market access training

(Logo: )

Drew Baker, President of Double Helix Consulting US, commented, "Ann complements our international market access, pricing and reimbursement capabilities through her vast experience in planning and implementing product development and launch strategies for the US market. Ann Stuchiner has led product planning initiatives in myriad therapeutic areas and has particular expertise in oncology, neurosciences, infectious disease, cardiometabolics, gastroenterology and pain. Her intimate knowledge of managed care market structure, formulary management, contracting strategies, and marketing communications strengthens Double Helix's ability to meet our clients' commercial objectives in the increasingly cost-conscious and value-driven US market."

Chief Executive Officer of Double Helix Development Group, Dr. Wayne Phillips, added, "Double Helix Consulting offers a premier set of services to assist our clients in optimizing product commercialization by enhancing market access through a truly global team of professionals with deep experience from both the client and consulting sides. As an example, our growing emerging markets practice provides clients with the intelligence to implement successful strategies in the world's largest and most rapidly developing economies. Ann's experience in product planning and launch strategy bolsters our expanding capabilities."

Stuchiner founded and led the Managed Markets Group at FCB HealthCare. Prior to FCB, her consulting career focused on development and implementation of managed market access strategy to support commercial development and product launches on behalf of major biopharmaceutical and device firms. She was also Director of MC(2), the managed care division of Lowe McAdams. Prior to her work in medical product commercialization strategy, Ann was a healthcare benefit design consultant for major employers and managed care organizations. She has served as an advisor to both the US Senate Subcommittee on Labor and Healthcare Issues and the New York State Department of Insurance. She is a graduate of Sarah Lawrence College and received her Master of Public Health degree from Columbia University.

SOURCE Double Helix Consulting US
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016
2. Tandem Labs New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
3. Sigma-Aldrich Achieves Double Accreditation as a Certified Reference Material Producer Following ISO/IEC 17025 and ISO Guide 34
4. Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits
5. Derma Sciences Expands Direct Sales Force for Advanced Wound Care, Looks to Double Again in 2008
6. The Center for Molecular Medicine Doubles Lab Staff, Expands Lab Space by 100 Percent
7. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
8. Double Resonance Probe for Liquid State NMR Applications From Varian, Inc. Increases Productivity for Routine Analyses
9. Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
10. Adoption of Spinal Nonfusion Technologies Doubled in One Year
11. Microtest Labs Doubles Microbial Identification, Analytical Services
Post Your Comments:
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... N.J. (PRWEB) , ... November 24, 2015 , ... The ... the recipient of the 2016 USGA Green Section Award. Presented annually since 1961, the ... through his or her work with turfgrass. , Clarke, of Iselin, N.J., ...
(Date:11/24/2015)... 2015 /CNW/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended September 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... said Andrew Rae , President & CEO ... not only value enriching for this clinical program, ...
(Date:11/24/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: AEZ) ... of the Toronto Stock Exchange, confirms that as of ... corporate developments that would cause the recent movements in ... --> About Aeterna Zentaris Inc. ... Aeterna Zentaris is a specialty biopharmaceutical company engaged ...
Breaking Biology Technology:
(Date:11/10/2015)... , Nov. 10, 2015 ... biometrics that helps to identify and verify the ... is considered as the secure and accurate method ... of a particular individual because each individual,s signature ... results especially when dynamic signature of an individual ...
(Date:11/2/2015)... 2015  SRI International has been awarded a contract ... services to the National Cancer Institute (NCI) PREVENT Cancer ... expertise, modern testing and support facilities, and analytical instrumentation ... toxicology studies to evaluate potential cancer prevention drugs. ... Cancer Drug Development Program is an NCI-supported pipeline to ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):